RATIONALE: Emphysema in chronic obstructive pulmonary disease (COPD) can be characterized by high-resolution chest computed tomography (HRCT); however, the repeated use of HRCT is limited because of concerns regarding radiation exposure and cost. OBJECTIVES: To evaluate biomarkers associated with emphysema and COPD-related clinical characteristics, and to assess the relationships of soluble receptor for advanced glycation endproducts (sRAGE), a candidate systemic biomarker identified in this study, with single-nucleotide polymorphisms (SNPs) in the gene coding for RAGE (AGER locus) and with clinical characteristics. METHODS: Circulating levels of 111 biomarkers were analyzed for association with clinical characteristics in 410 patients with COPD enrolled in the TESRA study. sRAGE was also measured in the ECLIPSE cohort in 1,847 patients with COPD, 298 smokers and 204 nonsmokers. The association between 21 SNPs in the AGER locus with sRAGE levels and clinical characteristics was also investigated. MEASUREMENTS AND MAIN RESULTS: sRAGE was identified as a biomarker of diffusing capacity of carbon monoxide and lung density in the TESRA cohort. In the ECLIPSE cohort, lower sRAGE levels were associated with increased emphysema, increased Global Initiative for Chronic Obstructive Lung Disease stage, and COPD disease status. The associations with emphysema in both cohorts remained significant after covariate adjustment (P < 0.0001). One SNP in the AGER locus, rs2070600, was associated with circulating sRAGE levels both in TESRA (P = 0.0014) and ECLIPSE (7.07 × 10(-16)), which exceeded genome-wide significance threshold. Another SNP (rs2071288) was also associated with sRAGE levels (P = 0.01) and diffusing capacity of carbon monoxide (P = 0.01) in the TESRA study. CONCLUSIONS: Lower circulating sRAGE levels are associated with emphysema severity and genetic polymorphisms in the AGER locus are associated with systemic sRAGE levels. Clinical trial registered with www.clinicaltrials.gov (NCT 00413205 and NCT 00292552).
RATIONALE: Emphysema in chronic obstructive pulmonary disease (COPD) can be characterized by high-resolution chest computed tomography (HRCT); however, the repeated use of HRCT is limited because of concerns regarding radiation exposure and cost. OBJECTIVES: To evaluate biomarkers associated with emphysema and COPD-related clinical characteristics, and to assess the relationships of soluble receptor for advanced glycation endproducts (sRAGE), a candidate systemic biomarker identified in this study, with single-nucleotide polymorphisms (SNPs) in the gene coding for RAGE (AGER locus) and with clinical characteristics. METHODS: Circulating levels of 111 biomarkers were analyzed for association with clinical characteristics in 410 patients with COPD enrolled in the TESRA study. sRAGE was also measured in the ECLIPSE cohort in 1,847 patients with COPD, 298 smokers and 204 nonsmokers. The association between 21 SNPs in the AGER locus with sRAGE levels and clinical characteristics was also investigated. MEASUREMENTS AND MAIN RESULTS: sRAGE was identified as a biomarker of diffusing capacity of carbon monoxide and lung density in the TESRA cohort. In the ECLIPSE cohort, lower sRAGE levels were associated with increased emphysema, increased Global Initiative for Chronic Obstructive Lung Disease stage, and COPD disease status. The associations with emphysema in both cohorts remained significant after covariate adjustment (P < 0.0001). One SNP in the AGER locus, rs2070600, was associated with circulating sRAGE levels both in TESRA (P = 0.0014) and ECLIPSE (7.07 × 10(-16)), which exceeded genome-wide significance threshold. Another SNP (rs2071288) was also associated with sRAGE levels (P = 0.01) and diffusing capacity of carbon monoxide (P = 0.01) in the TESRA study. CONCLUSIONS: Lower circulating sRAGE levels are associated with emphysema severity and genetic polymorphisms in the AGER locus are associated with systemic sRAGE levels. Clinical trial registered with www.clinicaltrials.gov (NCT 00413205 and NCT 00292552).
Authors: Francesca Polverino; Maria E Laucho-Contreras; Hans Petersen; Vanesa Bijol; Lynette M Sholl; Mary E Choi; Miguel Divo; Victor Pinto-Plata; Alfredo Chetta; Yohannes Tesfaigzi; Bartolomé R Celli; Caroline A Owen Journal: Am J Respir Crit Care Med Date: 2017-06-01 Impact factor: 21.405
Authors: Michael H Cho; Peter J Castaldi; Craig P Hersh; Brian D Hobbs; R Graham Barr; Ruth Tal-Singer; Per Bakke; Amund Gulsvik; Raúl San José Estépar; Edwin J R Van Beek; Harvey O Coxson; David A Lynch; George R Washko; Nan M Laird; James D Crapo; Terri H Beaty; Edwin K Silverman Journal: Am J Respir Crit Care Med Date: 2015-09-01 Impact factor: 21.405
Authors: Ani Manichaikul; Eric A Hoffman; Joanna Smolonska; Wei Gao; Michael H Cho; Heather Baumhauer; Matthew Budoff; John H M Austin; George R Washko; J Jeffrey Carr; Joel D Kaufman; Tess Pottinger; Charles A Powell; Cisca Wijmenga; Pieter Zanen; Harry J M Groen; Dirkje S Postma; Adam Wanner; Farshid N Rouhani; Mark L Brantly; Rhea Powell; Benjamin M Smith; Dan Rabinowitz; Leslie J Raffel; Karen D Hinckley Stukovsky; James D Crapo; Terri H Beaty; John E Hokanson; Edwin K Silverman; Josée Dupuis; George T O'Connor; H Marike Boezen; Stephen S Rich; R Graham Barr Journal: Am J Respir Crit Care Med Date: 2014-02-15 Impact factor: 21.405
Authors: Yong Zhou; Jeffrey C Horowitz; Alexandra Naba; Namasivayam Ambalavanan; Kamran Atabai; Jenna Balestrini; Peter B Bitterman; Richard A Corley; Bi-Sen Ding; Adam J Engler; Kirk C Hansen; James S Hagood; Farrah Kheradmand; Qing S Lin; Enid Neptune; Laura Niklason; Luis A Ortiz; William C Parks; Daniel J Tschumperlin; Eric S White; Harold A Chapman; Victor J Thannickal Journal: Matrix Biol Date: 2018-03-08 Impact factor: 11.583
Authors: Carrie P Aaron; Joseph E Schwartz; Suzette J Bielinski; Eric A Hoffman; John H M Austin; Elizabeth C Oelsner; Kathleen M Donohue; Ravi Kalhan; Cecilia Berardi; Joel D Kaufman; David R Jacobs; Russell P Tracy; R Graham Barr Journal: Respir Med Date: 2014-10-22 Impact factor: 3.415